Menu
News
Recent news
Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.
January 20, 2022
It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent Inflamm-ageing and slow down functional decline in the elderly.
September 30, 2021
Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.
March 17, 2021
Data clearly showed that the application of Santersus’ highly selective therapeutic apheresis technology was able to remove circulating Neutrophil Extracellular Traps (NETs) in a randomised, sham-controlled study.
January 11, 2021
First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®
December 2, 2021
Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients
November 26, 2021
Santersus’ Shareholders Elect New Board Members
September 22, 2021
Santersus AG Confirms Attendance at BioTech Gate
September 1, 2021
Santersus Raises CHF 750 thousand in Family & Friends Round
1 2 3 >
All news
Ageing and rejuvenation
January 20, 2022
Santersus completes first clinical trial for sepsis and Covid-19 treatment
September 30, 2021
Santersus’ therapeutic technology helps to treat sepsis
March 17, 2021